5472-54-8 Usage
Uses
Given the provided materials, specific uses for 2-(3-nitrophenyl)-4,5-bis(4-phenoxyphenyl)-1H-imidazole are not detailed. However, based on the general applications of imidazole derivatives, we can infer potential uses in various industries:
Used in Pharmaceutical Industry:
2-(3-nitrophenyl)-4,5-bis(4-phenoxyphenyl)-1H-imidazole could be used as a pharmaceutical agent for its potential biological activities, which may include medicinal properties that could be harnessed for the treatment of various conditions. The specific application reason would depend on the biological activity it exhibits once studied.
Used in Agrochemical Industry:
In the agrochemical sector, 2-(3-nitrophenyl)-4,5-bis(4-phenoxyphenyl)-1H-imidazole might be utilized as a component in pesticides or fungicides, leveraging its potential bioactive properties to control or prevent crop diseases and pests.
Used in Functional Materials:
For the development of functional materials, 2-(3-nitrophenyl)-4,5-bis(4-phenoxyphenyl)-1H-imidazole could be employed as a component in the creation of new materials with specific properties, such as light absorption, electrical conductivity, or catalytic activity, depending on its chemical characteristics.
Further research and experimentation would be necessary to confirm these potential uses and to explore additional applications based on the compound's properties.
Check Digit Verification of cas no
The CAS Registry Mumber 5472-54-8 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,4,7 and 2 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 5472-54:
(6*5)+(5*4)+(4*7)+(3*2)+(2*5)+(1*4)=98
98 % 10 = 8
So 5472-54-8 is a valid CAS Registry Number.
5472-54-8Relevant academic research and scientific papers
MLKL INHIBITORS
-
, (2018/09/26)
Purine derivatives that inhibit cellular necroptosis and/or human MLKL, pharmaceutical compositions thereof, and methods of treating an MLKL-mediated disorder with an effective amount of the compound or composition. Said MLKL-mediated disorder is pathology associated necroptosis, including ischemia-reperfusion damage, neurodegeneration, and inflammatory diseases such as acute pancreatitis, multiple sclerosis, inflammatory bowel disease, and allergic colitis.
Discovery of a new class of highly potent necroptosis inhibitors targeting the mixed lineage kinase domain-like protein
Yan, Bo,Liu, Lei,Huang, Shaoqiang,Ren, Yan,Wang, Huayi,Yao, Zhenglin,Li, Lin,Chen, She,Wang, Xiaodong,Zhang, Zhiyuan
, p. 3637 - 3640 (2017/04/03)
We report the development of novel Mixed Lineage Kinase Domain-Like protein (MLKL) inhibitors with single nanomolar potency (compound 15 is also named as TC13172). Using the converting biochemistry to chemistry activity-based protein profiling (BTC-ABPP) method, we were able to determine that the inhibitors covalently bind to Cysteine86 (Cys-86) of MLKL. This is the first example of the use of LC-MS/MS to identify the binding site of an MLKL inhibitor. The novel MLKL inhibitors provide powerful tools to study the biological function of MLKL and demonstrate that MLKL should be viewed as a druggable target.
